Back to search
FDAFDA · Food and drugs·Recall number D-0478-2023

Ropinirole, USP, 0.25 mg Tablets, Rx Only, Packaged as a 30-count bottle, NDC 72189-0364-30; Packaged and Distributed By: Direct Rx, Dawsonville, GA 30534

Published April 5, 2023 · Recall initiated: March 13, 2023

Summary

FDA records drug Class II recall D-0478-2023, published April 5, 2023 and initiated March 13, 2023. Recalling firm: Direct Rx; Status: Terminated; Reported quantity: 9 bottles; Lot: Lot, expiry: 21JU2210, exp 7/31/23. Class II means possible temporary or medically reversible effects, or a remote probability of serious health consequences.

Status when published: Terminated — openFDA updates weekly, so this field may not reflect the current status. Always confirm with the official notice.

What's the hazard

cGMP deviations

What to do

Voluntary: Firm initiated · Letter

Get an email when a new FDA recall like this is published

Free. We only write when there's a new recall that matches. Unsubscribe in one click.

Recall details

Manufacturer
Direct Rx
Distributor
Nationwide in the USA
Lot
Lot, expiry: 21JU2210, exp 7/31/23
Risk classification
Class II
Area (FDA)
drug
Country
United States

Related recalls

Questions about this recall

Was Ropinirole, USP, 0.25 mg Tablets, Rx Only, Packaged as a 30-count bottle, NDC 72189-0364-30; Packaged and Distributed By: Direct Rx, Dawsonville, GA 30534 recalled?

Yes. FDA published recall D-0478-2023 on April 5, 2023. Reported hazard: cGMP deviations

What should I do if I have this product?

Voluntary: Firm initiated · Letter